Ondine Biomedical, Inc. ( (GB:OBI) ) has issued an update.
Ondine Biomedical Inc. announced a significant reduction in surgical site infections (SSI) by 71% at Mid Yorkshire Teaching NHS Trust through the use of its Steriwave nasal photodisinfection technology. This deployment not only improved patient outcomes but also demonstrated cost savings and reduced hospital bed days, highlighting the potential for broader adoption in healthcare settings to combat hospital-acquired infections and antibiotic resistance.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has a range of investigational products based on this technology, including the Steriwave nasal photodisinfection system, which is approved in several countries and undergoing clinical trials in the US for regulatory approval. Ondine’s products target various medical conditions such as chronic sinusitis and ventilator-associated pneumonia.
YTD Price Performance: 11.43%
Average Trading Volume: 266,343
Technical Sentiment Signal: Hold
Current Market Cap: £43.22M
See more insights into OBI stock on TipRanks’ Stock Analysis page.